Abstract
BackgroundCurrent treatments for HSV infection are imperfect, do not completely abrogate viral shedding or transmission, and do not interrupt HSV-2—HIV interactions. AIC316 is a helicase-primase inhibitor, a new class of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have